Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia

Imagem de Miniatura
Arquivos
art_KITTEL-SCHNEIDER_Influence_of_DGKH_variants_on_amygdala_volume_in_2015.PDF (300.9 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
KITTEL-SCHNEIDER, S.
WOBROCK, T.
SCHERK, H.
SCHNEIDER-AXMANN, T.
TROST, S.
ZILLES, D.
WOLF, C.
MALCHOW, B.
HASAN, A.
Citação
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v.265, n.2, p.127-136, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The diacylglycerol kinase eta (DGKH) gene, first identified in a genome-wide association study, is one of the few replicated risk genes of bipolar affective disorder (BD). Following initial positive studies, it not only was found to be associated with BD but also implicated in the etiology of other psychiatric disorders featuring affective symptoms, rendering DGKH a cross-disorder risk gene. However, the (patho-)physiological role of the encoded enzyme is still elusive. In the present study, we investigated primarily the influence of a risk haplotype on amygdala volume in patients suffering from schizophrenia or BD as well as healthy controls and four single nucleotide polymorphisms conveying risk. There was a significant association of the DGKH risk haplotype with increased amygdala volume in BD, but not in schizophrenia or healthy controls. These findings add to the notion of a role of DGKH in the pathogenesis of BD.
Palavras-chave
DGKH, Bipolar disorder, Schizophrenia, Amygdala, Structural MRI
URI
https://observatorio.fm.usp.br/handle/OPI/9608
Referências
  1. Abrial E, 2011, MOL NEUROBIOL, V44, P407, DOI 10.1007/s12035-011-8210-4
  2. Arnone D, 2009, BRIT J PSYCHIAT, V195, P194, DOI 10.1192/bjp.bp.108.059717
  3. Barnett JH, 2009, NEUROSCIENCE, V164, P331, DOI 10.1016/j.neuroscience.2009.03.080
  4. Baum AE, 2008, MOL PSYCHIATR, V13, P197, DOI 10.1038/sj.mp.4002012
  5. Blond BN, 2012, BIPOLAR DISORD, V14, P340, DOI 10.1111/j.1399-5618.2012.01015.x
  6. BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031
  7. Buhle JT, 2014, CEREB CORTEX, V24, P2981, DOI 10.1093/cercor/bht154
  8. Chen G, 2000, BIPOLAR DISORD, V2, P217, DOI 10.1034/j.1399-5618.2000.20303.x
  9. DelBello MP, 2006, CNS SPECTRUMS, V11, P298
  10. Domschke Katharina, 2012, Curr Top Behav Neurosci, V12, P463, DOI 10.1007/7854_2011_185
  11. Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BRM.41.4.1149
  12. Foland LC, 2008, NEUROREPORT, V19, P221, DOI 10.1097/WNR.0b013e3282f48108
  13. Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871
  14. Hajek T, 2012, BIPOLAR DISORD, V14, P261, DOI 10.1111/j.1399-5618.2012.01013.x
  15. Hajek T, 2009, J AFFECT DISORDERS, V115, P395, DOI 10.1016/j.jad.2008.10.007
  16. Hajek T, 2012, J PSYCHIATR NEUROSCI, V37, P333, DOI 10.1503/jpn.110143
  17. Hallahan B, 2011, BIOL PSYCHIAT, V69, P326, DOI 10.1016/j.biopsych.2010.08.029
  18. Honea R, 2005, AM J PSYCHIAT, V162, P2233, DOI 10.1176/appi.ajp.162.12.2233
  19. Lichtenstein P, 2009, LANCET, V373, P234, DOI 10.1016/S0140-6736(09)60072-6
  20. Manji HK, 1999, BIOL PSYCHIAT, V46, P1328, DOI 10.1016/S0006-3223(99)00235-8
  21. Moore GJ, 2000, LANCET, V356, P1241, DOI 10.1016/S0140-6736(00)02793-8
  22. Moya PR, 2010, INT J NEUROPSYCHOPH, V13, P1127, DOI 10.1017/S1461145710000593
  23. Ollila HM, 2009, MOL PSYCHIATR, V14, P351, DOI 10.1038/mp.2008.122
  24. Pessoa L, 2010, NAT REV NEUROSCI, V11, P773, DOI 10.1038/nrn2920
  25. Pfeifer JC, 2008, J AM ACAD CHILD PSY, V47, P1289, DOI 10.1097/CHI.0b013e318185d299
  26. Pfennig A, 2013, DTSCH ARZTEBL INT, V110, P92, DOI 10.3238/arztebl.2013.0092
  27. Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X
  28. Savitz J, 2012, BRAIN BEHAV IMMUN, V31, P161
  29. Schmitt A, 2009, ACTA NEUROPATHOL, V117, P395, DOI 10.1007/s00401-008-0430-y
  30. Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1
  31. Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2
  32. Steckert AV, 2012, CURR NEUROVASC RES, V9, P47
  33. SWAYZE VW, 1992, BIOL PSYCHIAT, V31, P221, DOI 10.1016/0006-3223(92)90046-3
  34. SWAYZE VW, 1990, ARCH GEN PSYCHIAT, V47, P1054
  35. Takata A, 2011, PSYCHIAT CLIN NEUROS, V65, P280, DOI 10.1111/j.1440-1819.2011.02193.x
  36. Tesli M, 2009, PSYCHIAT GENET, V19, P269, DOI 10.1097/YPG.0b013e32832d302f
  37. Topham MK, 2009, BBA-GEN SUBJECTS, V1790, P416, DOI 10.1016/j.bbagen.2009.01.010
  38. Townsend J, 2012, BIPOLAR DISORD, V14, P326, DOI 10.1111/j.1399-5618.2012.01021.x
  39. Tu-Sekine Becky, 2013, Advances in Biological Regulation, V53, P118, DOI 10.1016/j.jbior.2012.09.007
  40. Usher J, 2010, ACTA PSYCHIAT SCAND, V121, P119, DOI 10.1111/j.1600-0447.2009.01428.x
  41. Usher J, 2010, PSYCHIAT RES-NEUROIM, V182, P1, DOI 10.1016/j.pscychresns.2009.09.004
  42. van Dongen J, 2013, AM J MED GENET B, V162B, P122, DOI 10.1002/ajmg.b.32135
  43. Weber H, 2011, NEUROPSYCHOPHARMACOL, V36, P2076, DOI 10.1038/npp.2011.98
  44. Whalley HC, 2012, NEUROPSYCHOPHARMACOL, V37, P919, DOI 10.1038/npp.2011.272
  45. Wolf C, 2014, EUR ARCH PSY CLIN N, V264, P93, DOI 10.1007/s00406-013-0427-y
  46. Yasuda S, 2009, J BIOL CHEM, V284, P29559, DOI 10.1074/jbc.M109.043604
  47. Yatham LN, 2013, BIPOLAR DISORD, V15, P1, DOI 10.1111/bdi.12025
  48. Yosifova A, 2011, GENES BRAIN BEHAV, V10, P789, DOI 10.1111/j.1601-183X.2011.00721.x
  49. Yu K, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00189
  50. Zeng Z, 2011, MOL PSYCHIATR, V16, P473, DOI 10.1038/mp.2010.86

Coleções
Artigos e Materiais de Revistas Científicas - LIM/27